INTERNATIONAL PATENT: NUCLIDIUM AG, UNIVERSITY OF BASEL FILES APPLICATION FOR "FIBROBLAST ACTIVATION PROTEIN-TARGETING RADIOPHARMACEUTICALS AND USES THEREOF"

GENEVA, Jan. 13 -- NUCLIDIUM AG (Im ErasmushausBaumleingasse 184051 Basel), UNIVERSITY OF BASEL (Vizerektorat ForschungPetersgraben 354001 Basel) filed a patent application (PCT/US2025/021148) for "FIBROBLAST ACTIVATION PROTEIN-TARGETING RADIOPHARMACEUTICALS AND USES THEREOF" on Mar 24, 2025. With publication no. WO/2026/010658, the details related to the patent application was published on Jan 08, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): JAAFAR-THIEL, Leila (Im ErasmushausBaumleingasse 184051 Basel), DE ROSE, Francesco (Im ErasmuhausBaumleingasse 184051 Basel), FANI, Melpomeni (Vizer...